Loading stock data…
SMMT
$18.66+0.58 (+3.21%)
After Hours$18.69+0.03 (+0.16%)· Last close May 11
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Summit Therapeutics Inc. in the Healthcare sector is trading at $18.66. The stock is currently 40% below its 52-week high of $30.98, remaining 4.0% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why SMMT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.66
Potential Upside
5%
Whystock Fair Value$19.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$30.38+62.8%
Range$12.10 – $44.95
Fundamentals
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-113.24%
Volume
Today's trading volume
3.89M
Recent News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts. For retail investors scanning headlines, the question is rarely about valuation multiples (most of these companies ... Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market
Summit Therapeutics (NASDAQ:SMMT) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 21, analysts at Stifel reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) and a $45 price target. The positive stance comes on the heels of Akeso announcing plans to disclose HARMONi-6 interim Overall […]
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch
Summit Therapeutics stock crashed Friday after the company said its lung cancer treatment didn't pass muster at an interim analysis.